Malcolm Campbell Memorial Award
Recognising outstanding research in chemistry and its application to the understanding of bioactivity.
Details
| Status | Closed |
|---|---|
| Career stage | All career stages |
Winners
Awarded on behalf of the team behind the discovery and early development of pirtobrutinib (Jaypirca), the first FDA and EMA approved reversible inhibitor of Bruton鈥檚 tyrosine kinase (BTK) for the treatment of mantle cell lymphoma.
BMCS congratulates the team on their success in producing second-generation BTK inhibitors that overcome limitations of the earlier compounds and provide promising clinical benefit for lymphoma cancer patients.
2023
Professors Anthony G.M Barrett, Matthew J. Fuchter, R. Charles Coombers and Simak Ali of Imperial College London for the discovery and early development of first-in-class cyclin-dependent kinase (CDK7) inhibitor, Samuraciclib for breast cancer.
2021
British scientists and clinical researchers who contributed to the COVID-19 response (received on their behalf by Sir Patrick Vallance, Chief Scientific Adviser to the Government of the UK)
2019
The FGFR discovery team: Christopher W Murray, Patrick Angibaud and Herbie Newell
Astex Pharmaceuticals, Janssen Pharmaceutica, and the Northern Institute for Cancer Research (NICR), Newcastle University
Development of Erdafitinib
2017
Osimertinib Team, AstraZeneca
Development of TAGRISSOTM
2015
Miles Congreve, Fiona Marshall and Malcom Weir, GPCR drug discovery BrilintaTM/BriliqueTM Team, AstraZeneca Development of BrilintaTM/BriliqueTM Paul O鈥橬eill, Kevin Park and Stephen Ward, University of Liverpool Research and Development of Anti-Malaria Agents Lawrence Woo, Barry Potter, University of Bath; and Atul Purohit, Michael Reed, Imperial College, London Discovery of Steroid Sulfatase Inhibitors Jonathan Bennett, Anton Bom, Alan Muir, Ronald Palin, David Rees and Ming Zhang, Organon Development of Sugammadex David O鈥橦agan, University of St Andrews Research on Fluorinating Enzymes Tony Wood, Pfizer Development of CCR5 Antagonists Malcolm Stevens, Andrew Westwell and Tracy Bradshaw, Cancer Research UK Discovery of the Anticancer Compound Fortress & Related Work2013
2011
2009
2007
2005
2003
About the prize
The Malcolm Campbell Memorial Prize is awarded biennially by the RSC BMCS to commemorate Professor Campbell鈥檚 outstanding contributions in a broad range of chemistry and their applications to the understanding of bioactivity.
The award comprises 拢2000 and a medal as well as one free attendance at an RSC BMCS conference in the year of the award.
Submissions are invited from individuals or teams in industry and academia with a British research centre mailing address although work may be from several worldwide groups.
Seminal publications which may include presentations in the public domain and/or patents from the submitting individual or team relating to work of biological and/or medicinal chemistry interest including discovery, process development, agrochemical and aromachemical research.
Submissions may be a culmination of a series of papers published in recent years prior to the award.
Submissions must be accompanied by written permission from Heads of Department or Managers for the release of the work details.
Awarded by the Biological and Medicinal Chemistry Sector
The group which to further the interests of all members of the RSC, both industrial and academic, involved in the pursuit and understanding of biologically active molecules. Predominant areas include pharmaceuticals, agrochemicals, flavours and fragrances.